Skip to main content
OpenTrials
Completed

NCT Number: NCT02975297

Exenatide Once Weekly for Smoking Cessation

The purpose of this study is to identify a potential new treatment for smoking cessation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

The University of Texas Health Science Center at Houston

Houston, Texas, 77030, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be English-speaking volunteers who desire to quit smoking and are willing to make a quit attempt during the course of the study;
  • Have smoked ≥10 cigarettes a day for at least one year and provide a breath carbon monoxide (CO) ≥10 ppm;
  • Have a negative pregnancy test, if female of childbearing potential;
  • Have HbA1C levels between 5.7 and 6.4% or BMI of or greater than 25 kg/square meters
  • Not currently using any therapy for glycemic control (either injectable [i.e. insulin] or oral agents);
  • Have vital signs as follows: resting pulse between 50 and 95 bpm, BP between 90-150 mmHg systolic and 45-95 mmHg diastolic;
  • Have hematology and chemistry laboratory tests that are within reference limits (within 10% above or below), with the following exception: pancreatic tests (lipase and amylase) must be within normal limits;
  • Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the principal investigator.

Exclusion criteria

  • Meet criteria for the following psychiatric and/or substance use disorders as assessed by the Mini International Neuropsychiatric Interview (MINI): items C (current manic or hypomanic episode only), I (alcohol abuse - Alcohol Addendum-past 3 months only; current alcohol dependence), J (substance abuse -Substance Abuse Addendum - past 3 months only; current substance dependence), K (current psychotic disorder or current mood disorder with psychotic features).
  • Individuals who meet criteria for non-exclusionary psychiatric disorders that are considered clinically unstable and/or unsuitable to participate as determined by the Principal Investigator and/or Study Physician.
  • Individuals rated as moderate (9-16) to high (17 or greater) on suicidality as assessed by Module B of the MINI.
  • Have personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2;
  • Have type 1 diabetes mellitus;
  • Have severe cardiovascular disease (history of myocardial infarction, life-threatening arrhythmia, or worsening angina pectoris);
  • Have active temporomandibular joint disease;
  • Have severe gastrointestinal disease (i.e. severe gastroparesis);
  • Have previous history of pancreatitis or are at risk for pancreatitis;
  • Have creatinine clearance (CrCl) < 30;
  • Have any previous medically adverse reaction to study medications, nicotine, or menthol;
  • Be pregnant or lactating or unwilling to provide a negative pregnancy test before study entry;
  • Not using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide);
  • Have any illness which in the opinion of the primary investigator would preclude safe and/or successful completion of the study.

Treatment and study plan

exenatide

Drug

Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.

Other names: Bydureon

NRT

Drug

Nicotine Patch (21mg) / 24 hours.

Other names: Nicotine patch

Counseling

Behavioral

Brief individual behavioral smoking cessation counseling.

Other names: Smoking cessation counseling

Placebo

Drug

Normal saline.

Primary outcomes

  1. Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm

    Time frame: 6 weeks

  2. Post-quit Craving as Assessed by the Questionnaire of Smoking Urges

    Time frame: 6 weeks

    Questionnaire of Smoking Urges (QSU) is a 10-item scale (total score range = 10-70, a lower score indicates lower cravings for cigarettes) that evaluates the intention and desire to smoke and anticipation of relief from withdrawal-associated negative affect.

  3. Withdrawal Symptoms as Assessed by the Wisconsin Smoking Withdrawal Scale

    Time frame: 6 weeks

    The Wisconsin Smoking Withdrawal Scale is a 28-item questionnaire designed to assess different aspects of the smoking withdrawal syndrome. Participants rate each item on a Likert scale from zero (strongly disagree) to four (strongly agree). Total score ranges from 0 to 112, with a higher score indicating greater withdrawal.

  4. Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges

    Time frame: 1 week

    Questionnaire of Smoking Urges (QSU) is a 10-item scale (total score range = 10-70, a lower score indicates lower cravings for cigarettes) that evaluates the intention and desire to smoke and anticipation of relief from withdrawal-associated negative affect.

  5. Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges

    Time frame: 3 weeks

    Questionnaire of Smoking Urges (QSU) is a 10-item scale (total score range = 10-70, a lower score indicates lower cravings for cigarettes) that evaluates the intention and desire to smoke and anticipation of relief from withdrawal-associated negative affect.

Secondary outcomes

  1. Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm

    Time frame: 7 weeks (1 week after end of treatment)

  2. Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm

    Time frame: 10 weeks (4 weeks after end of treatment)

  3. Post-quit Craving as Assessed by the Questionnaire of Smoking Urges

    Time frame: 7 weeks (1 week after end of treatment)

    Questionnaire of Smoking Urges (QSU) is a 10-item scale (total score range = 10-70, a lower score indicates lower cravings for cigarettes) that evaluates the intention and desire to smoke and anticipation of relief from withdrawal-associated negative affect.

  4. Post-quit Craving as Assessed by the Questionnaire of Smoking Urges

    Time frame: 10 weeks (4 weeks after end of treatment)

    Questionnaire of Smoking Urges (QSU) is a 10-item scale (total score range = 10-70, a lower score indicates lower cravings for cigarettes) that evaluates the intention and desire to smoke and anticipation of relief from withdrawal-associated negative affect.

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Registry information

Official study title

Exenatide Once Weekly for Smoking Cessation: A Randomized Clinical Trial

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Nov 29, 2016
Registry last updated
Jan 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.